The long-term objectives of this project are to characterize the interaction between dietary isoflavone and MDM2 oncogene, to evaluate the potential of MDM2 as novel targets for cancer chemoprevention, and to translate these findings into more rational approach to prevention of human cancers. Genistein is a dietary isoflavone known to have chemopreventive effects in several human cancer models, including those of the breasts and prostate. However, the mechanisms for its cancer preventive and growth inhibitory effects are not fully understood. The MDM2 oncoprotein has p53-dependent and -independent tumorigenic activities in various types of human cancers including prostate and breast cancers. It also has been suggested as a novel target for cancer prevention and treatment. This proposal is based on our preliminary data that support a previously unrecognized mechanism of action for genistein: direct down-regulation of the MDM2 oncogene. We have demonstrated that, in a dose-dependent manner, genistein inhibits MDM2 expression in human cancer cells (and normal cells), and that the inhibitory effects occur at both transcriptional and post-translational levels, and that the inhibitory effects occur in vivo and are related to genitein's anti-tumor effects. This proposal is designed to test the central hypothesis that inhibition of MDM2 is the major mechanism by which genistein exerts its anti-cancer effects. Three hypothesis-driven specific aims are proposed: 1). to establish that genistein specifically inhibits MDM2 and that this inhibition is the primary mechanism by which the compound exerts its anti-cancer effects.; 2). to evaluate the in vivo effects of genistein on MDM2 with respect to its cancer preventive effects; and 3). to determine the mechanisms by which genistein regulates MDM2. Successful completion of the specific aims will provide a basis for further investigation of MDM2 as a target for cancer prevention and treatment and will generate knowledge with respect to mechanisms of action for genistein (and maybe other dietary isoflavones)-based cancer control approaches. There also is considerable potential of exploiting MDM2-associated pathways for human cancer prevention and therapy. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA121211-02
Application #
7472597
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Davis, Cindy D
Project Start
2007-08-01
Project End
2012-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
2
Fiscal Year
2008
Total Cost
$275,500
Indirect Cost
Name
University of Alabama Birmingham
Department
Pharmacology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Feng, Liang; Yao, Hang-Ping; Zhou, Yong-Qing et al. (2016) Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res 35:70
Qin, Jiang-Jiang; Wang, Wei; Voruganti, Sukesh et al. (2015) Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget 6:33106-19
Yu, Jun-Xian; Voruganti, Sukesh; Li, Dan-Dan et al. (2015) Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. Chin J Nat Med 13:554-60
Wang, Wei; Nag, Subhasree A; Zhang, Ruiwen (2015) Targeting the NF?B signaling pathways for breast cancer prevention and therapy. Curr Med Chem 22:264-89
Wang, Wei; Qin, Jiang-Jiang; Voruganti, Sukesh et al. (2015) Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev 35:1220-67
Wang, Wei; Nag, Subhasree; Zhang, Xu et al. (2015) Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications. Med Res Rev 35:225-85
Feng, Liang; Wang, Wei; Yao, Hang-Ping et al. (2015) Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases. Methods Mol Biol 1233:151-9
Voruganti, Sukesh; Qin, Jiang-Jiang; Sarkar, Sushanta et al. (2015) Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action. Oncotarget 6:21379-94
Sharma, Sharad; Yao, Hang-Ping; Zhou, Yong-Qing et al. (2014) Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics. Mol Oncol 8:469-82
Zeng, Jun-Ying; Sharma, Sharad; Zhou, Yong-Qing et al. (2014) Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Mol Cancer Ther 13:37-48

Showing the most recent 10 out of 50 publications